Executive Summary
Palatin Technologies reported a materially loss-making QQ1 2025, with net income of -$7.8236 million and an EPS of -$0.39. Reported revenue data is not disclosed for the quarter, while cost of revenue amounted to $169,988 and total operating expenses reached $7.7647 million, driven primarily by R&D outlays of $5.7438 million. EBITDA stood at -$7.7369 million and operating income at -$7.7647 million, underscoring a high cash burn typical of biotech companies in active development phases. The quarterly cash burn translated into a net decrease in cash of $7.143 million, leaving cash and cash equivalents of approximately $2.384 million at period end. Balance sheet metrics show a fragile liquidity profile: total current liabilities at $9.8617 million against cash of $2.384 million, and a current ratio of 0.27. Notably, stockholders’ equity is negative at -$7.686 million, indicating accumulated losses and a weak equity base, underscoring continued reliance on external financing or milestone-based funding to support pipeline progression. While near-term revenue visibility remains unclear, Palatin’s strength lies in its diversified pipeline targeting MC receptor pathways (e.g., PL8177, PL9643, PL3994, PL5028) and the marketed product Vyleesi. The absence of a formal management forward guidance for QQ2 2025 leaves investors focused on upcoming clinical milestones, potential partnerships, and licensing opportunities as key catalysts. Overall, the stock remains a high-risk, high-reward exposure to the biotech sector with substantial execution risk but meaningful upside optionality if pivotal pipeline data or strategic partnerships materialize.
Key Performance Indicators
Key Insights
Revenue: not disclosed for QQ1 2025; Gross Profit: -$169,988.00; Gross Profit Margin: N/A; Operating Income: -$7,764,685.00; EBITDA: -$7,736,919.00; Net Income: -$7,823,649.00; EPS: -$0.39; R&D Expenses: $5,743,754.00; SG&A Expenses: $2,020,931.00; Interest Expense: $5,940.00; Depreciation & Amortization: $80,790.00; Cash from Operating Activities: -$7,016,213.00; Free Cash Flow: -$7,016,213.00; Cash at End of Period: $2,384,214.00; Total Assets: $3,415,259.00; Total Liabilities: $11...
Financial Highlights
Revenue: not disclosed for QQ1 2025; Gross Profit: -$169,988.00; Gross Profit Margin: N/A; Operating Income: -$7,764,685.00; EBITDA: -$7,736,919.00; Net Income: -$7,823,649.00; EPS: -$0.39; R&D Expenses: $5,743,754.00; SG&A Expenses: $2,020,931.00; Interest Expense: $5,940.00; Depreciation & Amortization: $80,790.00; Cash from Operating Activities: -$7,016,213.00; Free Cash Flow: -$7,016,213.00; Cash at End of Period: $2,384,214.00; Total Assets: $3,415,259.00; Total Liabilities: $11,100,864.00; Stockholders’ Equity: -$7,685,605.00; Current Ratio: 0.265; Quick Ratio: 0.265; Net Debt: -$1,913,720.00; Debt: $470,494.00; Cash Balance: $2,384,214.00; Negative Equity Indicates Ongoing Accumulated Losses and Financing Needs.
Income Statement
| Metric |
Value |
YoY Change |
QoQ Change |
| Gross Profit |
-169.99K |
-106.49% |
-119.59% |
| Operating Income |
-7.76M |
-27.10% |
6.92% |
| Net Income |
-7.82M |
-32.87% |
5.17% |
| EPS |
-0.39 |
18.75% |
30.36% |
Key Financial Ratios
operatingCashFlowPerShare
$-0.35
freeCashFlowPerShare
$-0.35
Management Commentary
Transcript data not provided in the available material. No earnings-call highlights or management quotes could be extracted for QQ1 2025. If a transcript becomes available, a themes-based synthesis (strategy, pipeline progression, market conditions, financial discipline) with contextual quotes will be added.
Forward Guidance
No formal forward guidance was issued for QQ2 2025 in the provided materials. Given the current cash burn and limited near-term revenue, Palatin’s guidance absence is not unusual for a biotech in active development. Investors should monitor: (1) upcoming data readouts or milestone achievements across the MC-receptor pipeline (PL8177, PL9643, PL3994, PL5028), (2) potential partnership or licensing agreements that could provide non-dilutive or diluted funding, and (3) any strategic actions to bolster liquidity (financing, equity raises, or debt facilities). The achievability of milestones will be a meaningful driver of equity value, particularly if efficacy signals or safety profiles materially improve the risk-reward profile.